Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $100 Million At-The-Market Offering Facility
Press Release – New York, NY – April 14, 2022 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a late-stage biotechnology company, in a $100 million At-The-Market offering facility (“ATM”).
The shares were registered on RLMD’s Registration Statement on Form S-3 (File No. 333-264189) filed with the Securities and Exchange Commission on April 7, 2022.
Jefferies LLC acted as agent for the ATM.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia and Barrett DiPaolo and associate Matt Siracusa.
- Sichenzia Ross Ference Carmel LLP Represents Aegis Capital Corp. in the $8.2 Million Private Placement of SOBRsafe, Inc. - October 8, 2024
- Sichenzia Ross Ference Carmel LLP represents A2Z Cust2Mate Solutions Corp. in $4 Million Registered Direct Offering - October 2, 2024
- Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $5.0 Million Offering - October 2, 2024